Circulating kidney injury molecule-1 (KIM-1) predicts survival outcomes in patients with metastatic renal cell carcinoma (mRCC), even in patients who have coexisting acute kidney injury (AKI) or ...
Oncorena is pleased to announce that the FDA has approved the Company's IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability ...
in the obstructed kidney an acute pyelonephritis with necrosis of the renal papillae, as well as cortical abscesses, was found — the exact analogue of the lesion found in the nondiabetic group ...
Orellanine is highly specific to the kidney and induces irreversible renal failure. It is clinically well-known that orellanine does not affect organs other than the kidneys. In pioneering ...
Renal cell carcinoma (RCC ... in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC, papillary RCC and chromophobe RCC. Angioscore is a ...
SESAUA annual meeting featured a kidney cancer session and a presentation by Dr. Robert Smith discussing how age and tumor ...
To be eligible for enrollment, patients must have histologically confirmed advanced clear cell or papillary RCC ... curative treatment of metastatic renal cell carcinoma in patients with no remaining ...
FOX6 News Milwaukee on MSN16d
Waukesha County deputy battling cancer, event raises nearly $25KA fundraiser to support a Waukesha County deputy as he battles cancer raised nearly $25,000 at the end of February.
Which Is a Better Investment, HUTCHMED (China) Limited or Ligand Pharmaceuticals Incorporated Stock?
Limited or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback